Clinical Trials
17 trialsNCT07627698 2026-06-04
DUET-MEL
Beijing Biotech
Phase 1/2 Recruiting
NCT05607095 2026-05-28
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT03686124 2026-05-13
ACTengine
Immatics US, Inc.
Phase 1/2 Recruiting
NCT04855435 2026-05-12
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
MonTa Biosciences ApS
Phase 1 Recruiting
NCT07015190 2026-05-06
Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences
Phase 3 Recruiting
NCT03025256 2026-05-05
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07203391 2026-04-23
TRIUMPH
St Vincent's Hospital, Sydney
Phase 1 Recruiting
NCT06414590 2026-04-14
Neoadjuvant Tebentafusp for Uveal Melanoma
Thomas Jefferson University
Phase 2 Recruiting
NCT06581406 2026-04-02
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune, Inc.
Phase 2/3 Recruiting
NCT05524935 2026-04-01
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06961357 2026-03-31
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT07276386 2026-03-31
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06550674 2026-03-19
IGCMU
Centre Jean Perrin
Phase NA Recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT07076550 2026-03-16
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Alpha-9 Oncology USA Inc.
Phase 1 Recruiting
NCT07364474 2026-03-11
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Massachusetts General Hospital
Phase NA Recruiting
NCT04792463 2026-03-09
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
Recruiting